Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
MDH-1
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "MDH-1" in MCE Product Catalog:
9
9 Publications Verification
Research Areas:
GNE-140 racemate is a racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and also a tautomer of GNE-140 (HY-118241). GNE-140 racemate is an orally active lactate dehydrogenase inhibitor, with an IC50 of 3 nM against human LDHA and an IC50 of 5 nM against LDHB. GNE-140 racemate reduces the phosphorylation level and total protein expression of p38 MAPK, and inhibits EGF-induced AKT phosphorylation. GNE-140 racemate decreases lactate production, regulates glycolysis, the pentose phosphate pathway and nucleotide biosynthesis, increases extracellular pH, inhibits cell proliferation, migration and invasion, and induces caspase-3 activation and ROS accumulation. GNE-140 racemate can be used in research related to breast cancer, cystic fibrosis and pancreatic cancer [1] .
1
1 Cited Publications
Research Areas:
MDH1-IN-2 (Compound 7c) is a selective MDH1 inhibitor, with IC50 values of 2.27 and 27.47 μM for MDH1 and MDH2, respectively. MDH1-IN-2 can reduce the generation of ROS by inhibiting the conversion of 2-Ketoglutaric acid (HY-W013636) to α-Hydroxyglutaric acid (HY-113038B) mediated by MDH1, thereby suppressing 2-Ketoglutaric acid (HY-W013636)-induced ferroptosis [1] .
1
1 Cited Publications
Target:
Research Areas:
MDH1-IN-1 is a selective MDH1 inhibitor with an IC50 of 6.79 μM against human targets. MDH1-IN-1 exhibits in vivo anti-tumor efficacy. MDH1-IN-1 can be used for the research of colorectal cancer [1].
Cat. No.: HY-W613220
CAS No.: 2143473-95-2
Research Areas:
MDH1/2-IN-1 is a MDH1/2 inhibitor (IC50: 1.07 μM and 1.06 μM respectively). MDH1/2-IN-1 inhibits mitochondrial respiration and the HIF-1α pathway. MDH1/2-IN-1 demonstrates significant anti-tumor potential. MDH1/2-IN-1 provides a new direction for the development of drugs targeting cancer metabolism [1].
Cat. No.: HY-RS08260
Target:
Research Areas:
MDH1 Human Pre-designed siRNA Set A contains three designed siRNAs for MDH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS16793
Target:
Research Areas:
Mdh1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mdh1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS23233
Target:
Research Areas:
Mdh1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mdh1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P70349
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MDH1; Diiodophenylpyruvate Reductase; Malate Dehydrogenase 1; Soluble Malate Dehydrogenase; Aromatic Alpha-Keto Acid Reductase; Malate Dehydrogenase; Malate Dehydrogenase, Cytoplasmic; HEL-S-32; Cytosolic Malate Dehydrogenase; MGC:1375; Malate Dehydrogena
Species:
Human
Source:
E. coli
Cat. No.: HY-P74757
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: MDH1; Diiodophenylpyruvate Reductase; Malate Dehydrogenase 1; Soluble Malate Dehydrogenase; Aromatic Alpha-Keto Acid Reductase; Malate Dehydrogenase; Malate Dehydrogenase, Cytoplasmic; HEL-S-32; Cytosolic Malate Dehydrogenase; MGC:1375; Malate Dehydrogena
Species:
Rat
Source:
E. coli
Cat. No.: HY-RS17185
Target:
Research Areas:
Me1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Me1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-100742R
CAS No.: 1802977-61-2
GNE-140 racemate (Standard) is the analytical standard of GNE-140 racemate (HY-100742). This product is intended for research and analytical applications. GNE-140 racemate is a racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and also a tautomer of GNE-140 (HY-118241). GNE-140 racemate is an orally active lactate dehydrogenase inhibitor, with an IC50 of 3 nM against human LDHA and an IC50 of 5 nM against LDHB. GNE-140 racemate reduces the phosphorylation level and total protein expression of p38 MAPK, and inhibits EGF-induced AKT phosphorylation. GNE-140 racemate decreases lactate production, regulates glycolysis, the pentose phosphate pathway and nucleotide biosynthesis, increases extracellular pH, inhibits cell proliferation, migration and invasion, and induces caspase-3 activation and ROS accumulation. GNE-140 racemate can be used in research related to breast cancer, cystic fibrosis and pancreatic cancer [1] .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
